Clinical Report: Quality of Life Challenges in Chronic Myeloid Leukemia
Overview
A nationwide survey of 146 patients with chronic myeloid leukemia (CML) revealed that 26% reported low or very low quality of life (QoL). The study identified persistent symptoms, particularly fatigue, weakness, and muscle pain, affecting patients' daily functioning.
Background
Chronic myeloid leukemia (CML) treatment has evolved significantly with the introduction of tyrosine kinase inhibitors (TKIs), improving patient outcomes. Long-term TKI therapy can lead to persistent symptoms that may affect patients' quality of life.
Data Highlights
The survey involved 146 adult patients with CML, revealing that 26% reported low or very low QoL, with fatigue, weakness, and muscle pain being the most common symptoms.
Key Findings
26% of patients reported low or very low quality of life.
Fatigue, weakness, and muscle pain were the most frequently reported symptoms.
Female patients experienced a higher symptom burden and greater psychological distress than males.
Chronic treatment-related adverse events contribute to a significant cumulative burden over time.
Clinical Implications
Healthcare providers should prioritize addressing the quality of life and symptom management in patients with CML, particularly in those receiving later lines of therapy. Enhanced communication regarding supportive services and long-term management strategies is essential to meet patient needs.
Conclusion
The findings indicate that patients with CML experience a significant burden related to their condition and treatment.
by Elisabetta Abruzzese, Mario Annunziata, Felice Bombaci, Antonella Russo Rossi, Anna Galante, Alessandra Misto, Diletta Valsecchi, Evgeniia Gushchina, Carmen Fava
